Invbio is the website for i&i Biotech Fund, a venture capital firm based in Luxembourg. The firm focuses on investing in innovative life sciences companies across Europe, particularly those involved in drug discovery, medical devices, diagnostics, and digital health. With over €45 million under management, i&i Biotech Fund plans to support around 20 early-stage companies, helping them progress towards commercial success.

The fund has a close partnership with i&i Prague, a biotech incubator, and also receives backing from the European Investment Fund, which supports strategic investments in promising technology-driven ventures across Europe. The firm typically invests in companies at the pre-seed, seed, and Series A/B stages, with typical investments ranging from €100,000 to €1.5 million.

The fund has been involved in notable investments like CasInvent Pharma, a Czech start-up developing new inhibitors for the treatment of leukemia and other tumors. i&i Biotech Fund is committed to supporting transformative technologies in Central Europe, leveraging its team's expertise in private equity, healthcare, and venture capital(EU-Startups)(BioSpace).

in touch

Biotech Fund is a Luxembourg-based venture capital firm investing in early-stage European life sciences companies. The fund primarily focuses on drug discovery, medical devices, diagnostics, and digital health. One of its key missions is to support innovative technologies and solutions in Central Europe, with strong connections to academic research and biotech incubators, especially through its collaboration with i&i Prague.

Learn more

Investment Strategy: i&i Biotech Fund targets early-stage companies, typically making investments between €100,000 and €1.5 million at the pre-seed, seed, and Series A/B stages. It emphasizes partnerships with academic innovators and spin-offs, facilitating the commercialization of groundbreaking research

Support from the European Investment Fund (EIF): i&i Biotech Fund benefits from backing by the EIF, with funds provided under initiatives such as the Horizon 2020 program and the European Fund for Strategic Investments (EFSI). These programs support innovation and help European companies access much-needed funding

Notable Investments: One of the fund’s key investments includes CasInvent Pharma, a spin-off from Masaryk University, which focuses on developing inhibitors targeting casein kinase 1 for leukemia and solid tumors. This partnership showcases i&i Biotech’s commitment to advancing transformative health technologies.

Close Partnership with i&i Prague: As a biotech incubator, i&i Prague plays a crucial role in identifying and nurturing promising scientific projects. This partnership allows i&i Biotech to be closely involved in the early stages of technology development, especially in Central European countries